Short Interest in Edwards Lifesciences Corp Drops By 45.6% (EW)
Shares of Edwards Lifesciences Corp (NYSE:EW) were the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 2,915,578 shares, a decline of 45.6% from the July 15th total of 5,356,970 shares, Stock Ratings Network.com reports. Based on an average daily trading volume, of 1,687,462 shares, the days-to-cover ratio is presently 1.7 days. Approximately 2.8% of the company’s shares are sold short.
In other Edwards Lifesciences Corp news, VP Patrick B. Verguet sold 7,800 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $95.50, for a total value of $744,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on EW. Analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences Corp from $78.00 to $90.00 in a research note on Thursday, July 31st. Finally, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Edwards Lifesciences Corp has an average rating of “Buy” and a consensus price target of $90.06.
Shares of Edwards Lifesciences Corp (NYSE:EW) opened at 97.89 on Tuesday. Edwards Lifesciences Corp has a 52 week low of $60.62 and a 52 week high of $98.27. The stock’s 50-day moving average is $89.6 and its 200-day moving average is $79.. The company has a market cap of $10.380 billion and a P/E ratio of 13.94.
Edwards Lifesciences Corp (NYSE:EW) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corp will post $3.29 earnings per share for the current fiscal year.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.